Vertex Pharmaceuticals Incorporated ( VRTX Quick Quote VRTX - Free Report) announced that the European Commission has approved label expansion of its combination regimen of Symkevi and Kalydeco. The regimen is now approved for treating cystic fibrosis (“CF”) patients aged six to 11 and who have two copies of the F508del mutation in the CFTR gene or one copy of the F508del mutation and one copy of one of 14 residual function mutations in the CFTR gene that result in residual CFTR activity (P67L, R117C, L206W, R352Q, A455E, D579G, 711+3A→G, S945L, S977F, R1070W, D1152H, 2789+5G→A, 3272-26A→G, and 3849+10kbC→T).
Please note that that the Symkevi and Kalydeco combo regimen is already approved for treating CF patients aged 12 years or older with same mutations.
The combination regimen will be available for additional eligible patient population immediately in Germany followed by the United Kingdom, Denmark and the Republic of Ireland. The company will start working closely with relevant authorities in Europe for securing access to the regimen for the new patient population in other countries of the European Union.
Shares of Vertex have increased 3.5% so far this year compared with the
industry’s 3.1% gain.
We note that Vertex markets four CF medicines, namely Kalydeco, Orkambi, Symdeko/Symkevi and Trikafta. Approximately 45,000 patients worldwide are now eligible to be treated with one of Vertex’s four CF medicines.
Notably, Trikafta is crucial for Vertex’s long-term growth as it has the potential to treat up to 90% of CF patients. Trikafta was approved under the trade name of Kaftrio in the EU in August 2020. The drug generated sales worth $2.8 billion in the first nine months of 2020. It has seen solid uptake since its early unveiling and has been a key driver for the company ever since.
Meanwhile, phase III studies are ongoing to evaluate Trikafta in children aged six to 11 years. An sNDA seeking approval for the product among this pediatric patient population is expected to be filed in the fourth quarter of 2020. The recent nod in Europe and a potential label expansion of the drug for younger patient population could bring additional revenues for Vertex this year as well as in 2021.
Meanwhile, Vertex is also looking to develop new treatment options using novel technologies for CF patients as well as other indications. In September, Vertex announced a new strategic research collaboration and licensing agreement with
Moderna ( MRNA Quick Quote MRNA - Free Report) to develop lipid nanoparticles (LNPs) and mRNAs to treat CF using gene editing. Vertex is also developing a gene therapy in partnership with CRISPR Therapeutics ( CRSP Quick Quote CRSP - Free Report) for treating transfusion-dependent beta thalassemia and sickle cell disease. Zacks Rank & Stock to Consider
Vertex currently carries a Zacks Rank #3 (Hold).
Catalyst Biosciences ( CBIO Quick Quote CBIO - Free Report) is a better-ranked biotech to consider, which carries a Zacks Rank #2 (Buy). You can see . the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here
Catalyst Biosciences’ loss estimates for 2021 have narrowed from $3.23 to $2.98 over the past 60 days.
The Hottest Tech Mega-Trend of All
Last year, it generated $24 billion in global revenues. By 2020, it's predicted to blast through the roof to $77.6 billion. Famed investor Mark Cuban says it will produce "the world's first trillionaires," but that should still leave plenty of money for regular investors who make the right trades early.
See Zacks' 3 Best Stocks to Play This Trend >>